EU REGULATORS BACKED A NEW PANCREATIC-CANCER PILL.
An EMA committee recommended a once-daily oral RAS inhibitor for eligible adults with metastatic pancreatic cancer.
A notoriously hard-to-treat cancer may soon have another targeted oral option in Europe.
WHAT HAPPENED
The European Medicines Agency's medicines committee recommended Rasonque (daraxonrasib), a once-daily oral RAS inhibitor, for certain adults with metastatic pancreatic ductal adenocarcinoma after at least one prior therapy or when combination treatment is unsuitable. The European Commission still has to make the final authorization decision.
WHY THIS IS HOPESLOP
Pancreatic cancer has offered patients too few options for too long. A new targeted pill is not a cure, and price and access may sharply limit who benefits, but another evidence-based route after treatment failure is real room to move.
ORIGINAL SOURCEEuropean Medicines AgencyRead the original report
A DAILY ALLEGATION OF PROGRESS.
One good thing from the internet, every day. Nothing else.